GSK receives Breakthrough Therapy Designation from FDA for meningitis B vaccine Bexsero
GlaxoSmithKline plc announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its meningitis B vaccine Bexsero for the…
Read More...
Read More...
